Status: Recruiting
Avo In R/R And Previously Untreated MCL
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinutuzumab
Participants needed: 72
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Austin I KimUpdated: Jan 21, 2026Locations: 3
Eligibility criteria
Relapsed or primary refractory after at least one line of therapy including anti... [+23]
Participants who have progressed or relapsed after receiving either a BTK inhibi... [+25]